Наукові праці. Кафедра фізичної та реабілітаційної медицини

Постійне посилання зібрання

https://repository.pdmu.edu.ua/handle/123456789/261

Переглянути

Перегляд Наукові праці. Кафедра фізичної та реабілітаційної медицини за Автор "Akimov, Oleh"

Зараз показуємо 1 - 2 з 2
  • Ескіз
    Документ
    Desmodium styracifolium: Botanical and ethnopharmacological insights, phytochemical investigations, and prospects in pharmacology and pharmacotherapy
    (Cell Press, 2024) Opryshko, Valentyna; Prokhach, Anna; Akimov, Oleh; Riabushko, Mykola; Kostenko, Heorhii; Kostenko, Viktoriia; Mishchenko, Artur; Solovyova, Natalia; Kostenko, Vitalii; Опришко, Валентина Іванівна; Прохач, Анна Володимирівна; Акімов, Олег Євгенович; Рябушко, Микола Миколайович; Костенко, Георгій Віталійович; Костенко, Вікторія Геннадіївна; Міщенко, Артур Володимирович; Соловйова, Наталія Веніамінівна; Костенко, Віталій Олександрович
    The purpose of this inquiry is to provide a conprehensive summary and analysis of the literature concerning the pharmacological properties of components that can be extracted from Desmodium styracifolium, a preparation in Chinese medicine. This study also aims to explore their potential application in elaborating medicinal products for the effective prevention and treatment of such conditions as urolithiasis, cholelithiasis, type 2 diabetes mellitus, metabolic syndrome, prooxidant and inflammatory processes, etc. Several experimental studies confirmed the potential of D. styracifolium to influence mineral metabolism, to decrease the concentration of constituents involved in the formation of urinary calculi, and to reduce mineral encrustation in the urinary tract, as well as to alleviate the damage caused by crystal structures. This beneficial impact is achieved through a combination of antioxidant and anti-inflammatory actions, along with urine alkalinization. The cholelitholytic, choleretic, and hepatoprotective effects of D. styracifolium plants have been confirmed, primarily ascribed to the activation of the hepatic Xα receptor and the bile acid receptor, farnesoid X receptor, by the flavonoid shaftoside. Special attention is focused on the potential therapeutic applications of flavonoids derived from D. styracifolium for diseases associated with the development of chronic inflammation and systemic response, emphasizing the ability of flavonoids to exert antioxidant and anti-inflammatory effects by acting directly and through the modulation of transcription factors. It is concluded that new strategies for the prevention and treatment of urolithiasis, cholelithiasis, type 2 diabetes mellitus, metabolic syndrome, acute and chronic inflammatory processes may rely on the promising development of dosage forms of D. styracifolium with their subsequent preclinical and clinical trials.
  • Ескіз
    Документ
    Therapeutic potential of 5-aminolevulinic acid in metabolic disorders: Current insights and future directions
    (Cell Press, 2024) Kuryata, Olexandr; Akimov, Oleh; Riabushko, Mykola; Kostenko, Heorhii; Kostenko, Viktoriia; Mishchenko, Artur; Nazarenko, Svetlana; Solovyova, Natalia; Kostenko, Vitalii; ‪Курята Олександр Вікторович; Акімов, Олег Євгенович; Рябушко, Микола Миколайович; Костенко, Георгій Віталійович; Костенко, Вікторія Геннадіївна; Міщенко, Артур Володимирович; Назаренко, Світлана Миколаївна; Соловйова, Наталія Веніамінівна; Костенко, Віталій Олександрович
    5-Aminolevulinic acid (5-ALA) is an essential compound in the biosynthesis of heme, playing a critical role in various physiological processes within the human body. This review provides the thorough analysis of the latest research on the molecular mechanisms and potential therapeutic benefits of 5-ALA in managing metabolic disorders. The ability of 5-ALA to influence immune response and inflammation, oxidative/nitrosative stress, antioxidant system, mitochondrial functions, as well as carbohydrate and lipid metabolism, is mediated by molecular mechanisms associated with the suppression of the transcription factor NF-kB signaling pathway, activation of the transcription factor Nrf2/heme oxygenase-1 (HO-1) system leading to the formation of heme-derived reaction products (carbon monoxide, ferrous iron, biliverdin, and bilirubin), which may contribute to HO-1- dependent cytoprotection through antioxidant and immunomodulatory effects. Additionally, it regulates the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, cytochrome c oxidase subunit IV, uncoupling proteins UCP1 and UCP2, glucose transporters GLUT1 and GLUT2, and sterol regulatory element-binding protein 1c in relevant tissues. Randomized controlled trials have confirmed the effects of 5-ALA on glucose control in both prediabetic and diabetic patients, noting its safety and tolerability, as well as the safety of its combined use with oral hypoglycemic agents. Only minor side effects have been reported. However, the impact of 5-ALA on markers of systemic inflammation, oxidative and nitrosative stress, and dyslipidemia was not evaluated in these studies. At the same time, preparations of 5-ALA may potentially be effective not only in the treatment of prediabetes and type 2 diabetes mellitus (T2DM), but also in other conditions associated with systemic inflammation, oxidative or nitrosative stress, mitochondrial dysfunction, as well as disorders of carbohydrate and lipid metabolism. It has been concluded that the promising advancement of formulations containing 5-ALA may pave the way for new strategies in preventing and treating these diseases, with subsequent preclinical and clinical trials likely to follow.